Intra-Cellular Therapies Inc.

Good morning, ladies and gentlemen, and welcome to Intracellular Therapy's first quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star 11 on your telephone. You would then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to your speaker today, Dr. Juan Sanchez, Vice President, Corporate Communication and Investor Relations. Please go ahead.

Good morning and thank you all for joining us on our first quarter 2024 earnings call.

Joining me today on the call are Dr. Sharon Nates, Chairman and Chief Executive Officer, Mark Newman, Chief Commercial Officer, Dr. Suresh Dorgam, Chief Medical Officer, and Larry Heinlein, Chief Financial Officer. The slides to help guide today's call are available on the Investor Events section of our corporate website. I'm on slide number two. During today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, and expectations. Those statements are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our quarterly and annual reports. You are cautioned not to place on due reliance on these forward-looking statements. These statements are made only as the date of this conference call, and the company claims any obligation to update such statements. I will now turn the call over to Sharon. Sharon will begin on slide four. Sharon?